NASDAQ:RLAY
Relay Therapeutics Inc. Stock News
$6.37
+0.215 (+3.49%)
At Close: Apr 26, 2024
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
04:05pm, Thursday, 25'th Apr 2024
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e
Relay Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 11'th Apr 2024
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e
3 Precision Medicine Stocks That Could Benefit From the Industry's Rise
12:39pm, Friday, 15'th Mar 2024
Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
10:56am, Wednesday, 13'th Mar 2024
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
04:05pm, Monday, 26'th Feb 2024
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
10:56am, Monday, 26'th Feb 2024
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
04:05pm, Thursday, 15'th Feb 2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
04:31am, Thursday, 15'th Feb 2024
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t
The 7 Best Penny Stocks for 200% Returns
02:57pm, Tuesday, 06'th Feb 2024
This year is going to offer a lot of opportunities for risk seeking investors. The world of penny stocks is well known to be speculative and is usually the domain of investors possessing a risk seekin
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 02'nd Jan 2024
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence
07:11pm, Thursday, 09'th Nov 2023
We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.
Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)
02:05am, Monday, 06'th Nov 2023
Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with am
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
07:42pm, Tuesday, 08'th Aug 2023
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.71 per share a year ago.
Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608
06:04am, Friday, 28'th Jul 2023
Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, anal
